Brief: Mineralys Therapeutics Filed NDA For Lorundrostat To U.S. FDA In Late 2025
06/01/2026 13:51
Jan 6 (Reuters) - Mineralys Therapeutics Inc MLYS.O: MINERALYS THERAPEUTICS INC - FILED NDA FOR LORUNDROSTAT TO U.S. FDA IN LATE 2025 MINERALYS THERAPEUTICS INC - CO REMAINS ON TRACK TO REPORT TOPLINE RESULTS FROM PHASE 2 EXPLORE-OSA TRIAL IN Q1 2026 Source text: ID:nGNXvdFxf Further company coverage: MLYS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mineralys Therapeutics
See all newsBrief: Mineralys Therapeutics Expands Its Board Of Directors With The Appointments Of Kristine Peterson And Lonnel Coats
Mineralys Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway